{"database": "lobbying", "table": "lobbying_activities", "rows": [[1198859, "b5284c51-daa3-43e1-b469-d410e9809f7b", "Q4", "PARRY, ROMANI, DECONCINI & SYMMS", 30792, "WEDGEWOOD VILLAGE PHARMACY, INC.", 2011, "fourth_quarter", "PHA", "Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens.   No specific legislation introduced yet. Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  No specific legislation has been introduced yet.\n\nProposals to amend the Controlled Substances Act to clarify the definition of \"dispense\" to include the delivery of a controlled substance by a practitioner acting in the usual course of professional practice.  No specific legislation yet.\n\nRegulatory issues involving compounded 17P and compounded Avastin.", "HOUSE OF REPRESENTATIVES,SENATE", 11250, null, 0, 0, "2012-01-19T17:30:28-05:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1198859"], "units": {}, "query_ms": 0.7817370351403952, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}